These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 21233289

  • 1. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor.
    Teraoka N, Mutoh M, Takasu S, Ueno T, Yamamoto M, Sugimura T, Wakabayashi K.
    Cancer Prev Res (Phila); 2011 Mar; 4(3):445-53. PubMed ID: 21233289
    [Abstract] [Full Text] [Related]

  • 2. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36.
    Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM, Nicholson AC.
    Circulation; 2004 Feb 17; 109(6):790-6. PubMed ID: 14970117
    [Abstract] [Full Text] [Related]

  • 3. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice.
    Mutoh M, Niho N, Komiya M, Takahashi M, Ohtsubo R, Nakatogawa K, Ueda K, Sugimura T, Wakabayashi K.
    Carcinogenesis; 2008 Apr 17; 29(4):824-9. PubMed ID: 18258607
    [Abstract] [Full Text] [Related]

  • 4. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice.
    Yasuda Y, Shimizu M, Shirakami Y, Sakai H, Kubota M, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H.
    Cancer Sci; 2010 Jul 17; 101(7):1701-7. PubMed ID: 20398056
    [Abstract] [Full Text] [Related]

  • 5. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway.
    Hiraoka M, Nitta N, Nagai M, Shimokado K, Yoshida M.
    Life Sci; 2004 Jul 30; 75(11):1333-41. PubMed ID: 15234191
    [Abstract] [Full Text] [Related]

  • 6. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice.
    Niho N, Mutoh M, Takahashi M, Tsutsumi K, Sugimura T, Wakabayashi K.
    Proc Natl Acad Sci U S A; 2005 Feb 22; 102(8):2970-4. PubMed ID: 15710887
    [Abstract] [Full Text] [Related]

  • 7. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.
    Yagi S, Aihara K, Ikeda Y, Sumitomo Y, Yoshida S, Ise T, Iwase T, Ishikawa K, Azuma H, Akaike M, Matsumoto T.
    Circ Res; 2008 Jan 04; 102(1):68-76. PubMed ID: 17967781
    [Abstract] [Full Text] [Related]

  • 8. Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
    Kumai T, Oonuma S, Matsumoto N, Takeba Y, Taniguchi R, Kamio K, Miyazu O, Koitabashi Y, Sekine S, Tadokoro M, Kobayashi S.
    Life Sci; 2004 Mar 12; 74(17):2129-42. PubMed ID: 14969717
    [Abstract] [Full Text] [Related]

  • 9. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice.
    Kurata T, Miyazaki K, Kozuki M, Panin VL, Morimoto N, Ohta Y, Nagai M, Ikeda Y, Matsuura T, Abe K.
    Brain Res; 2011 Jan 31; 1371():161-70. PubMed ID: 21112317
    [Abstract] [Full Text] [Related]

  • 10. Increase of oxidant-related triglycerides and phosphatidylcholines in serum and small intestinal mucosa during development of intestinal polyp formation in Min mice.
    Ikeda K, Mutoh M, Teraoka N, Nakanishi H, Wakabayashi K, Taguchi R.
    Cancer Sci; 2011 Jan 31; 102(1):79-87. PubMed ID: 20946475
    [Abstract] [Full Text] [Related]

  • 11. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104).
    Han J, Parsons M, Zhou X, Nicholson AC, Gotto AM, Hajjar DP.
    Circulation; 2004 Nov 30; 110(22):3472-9. PubMed ID: 15557368
    [Abstract] [Full Text] [Related]

  • 12. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients.
    Nomura S, Shouzu A, Omoto S, Inami N, Shimazu T, Satoh D, Kajiura T, Yamada K, Urase F, Maeda Y, Iwasaka T.
    Blood Coagul Fibrinolysis; 2009 Sep 30; 20(6):440-7. PubMed ID: 19525846
    [Abstract] [Full Text] [Related]

  • 13. Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.
    Mutoh M, Niho N, Wakabayashi K.
    Biol Chem; 2006 Apr 30; 387(4):381-5. PubMed ID: 16606335
    [Abstract] [Full Text] [Related]

  • 14. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
    Kuwahara N, Sasaki S, Kobara M, Nakata T, Tatsumi T, Irie H, Narumiya H, Hatta T, Takeda K, Matsubara H, Hushiki S.
    Int J Cardiol; 2008 Jan 11; 123(2):84-90. PubMed ID: 17434618
    [Abstract] [Full Text] [Related]

  • 15. Pitavastatin attenuates leukocyte-endothelial interactions induced by ischemia-reperfusion injury in the rat retina.
    Miyaki K, Matsubara A, Nishiwaki A, Tomida K, Morita H, Yoshida M, Ogura Y.
    Curr Eye Res; 2009 Jan 11; 34(1):10-7. PubMed ID: 19172465
    [Abstract] [Full Text] [Related]

  • 16. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
    Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, Sugimura T, Wakabayashi K.
    Cancer Res; 2003 Sep 15; 63(18):6090-5. PubMed ID: 14522940
    [Abstract] [Full Text] [Related]

  • 17. Pitavastatin fails to lower serum lipid levels or inhibit gastric carcinogenesis in helicobacter pylori-infected rodent models.
    Toyoda T, Tsukamoto T, Takasu S, Hirano N, Ban H, Shi L, Kumagai T, Tanaka T, Tatematsu M.
    Cancer Prev Res (Phila); 2009 Aug 15; 2(8):751-8. PubMed ID: 19622613
    [Abstract] [Full Text] [Related]

  • 18. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells.
    Kibayashi E, Urakaze M, Kobashi C, Kishida M, Takata M, Sato A, Yamazaki K, Kobayashi M.
    Clin Sci (Lond); 2005 Jun 15; 108(6):515-21. PubMed ID: 15701058
    [Abstract] [Full Text] [Related]

  • 19. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell.
    Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y.
    Biochem Biophys Res Commun; 2004 Nov 12; 324(2):835-9. PubMed ID: 15474503
    [Abstract] [Full Text] [Related]

  • 20. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts.
    Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, Takayanagi R.
    Biochem Biophys Res Commun; 2001 Sep 21; 287(2):337-42. PubMed ID: 11554731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.